GlassScriptPhysician profile
Jason J Li
NPI 1033122676
$16,502.06
in general payments reported to CMS, 2019-2025
66 companies · $4,168 in 2025
The $4,168 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $455 · 2021: $1,741 · 2022: $2,134 · 2023: $3,543 · 2024: $2,627 · 2025: $4,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,198 · Consulting Fee: $1,650 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,294 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,198.18 |
| Consulting Fee | $1,650.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,293.75 |
| Education | $195.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,048.30 | 2019-2025 | Imbruvica, Talvey, Darzalex |
| Beone Medicines USA, INC. | $1,765.38 | 2025 | Tevimbra, Brukinsa |
| Cti Biopharma Corp. | $1,357.29 | 2022-2023 | Vonjo |
| Novartis Pharmaceuticals Corporation | $1,288.42 | 2019-2025 | |
| Pfizer INC. | $738.54 | 2019-2025 | |
| Genentech USA, INC. | $663.81 | 2019-2025 | Tecentriq, Venclexta, Perjeta |
| Celgene Corporation | $586.67 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| Merck Sharp & Dohme LLC | $544.97 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $478.35 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Seagen INC. | $476.58 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Abbvie INC. | $459.12 | 2019-2025 | |
| Incyte Corporation | $368.69 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $315.58 | 2022-2025 | Iclusig, Alunbrig |
| Genzyme Corporation | $302.60 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $272.04 | 2019-2025 | Opdivo, Krazati, Opdualag |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $257.11 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $244.27 | 2022-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $236.72 | 2019-2023 | Imbruvica, Epkinly |
| Eisai INC. | $235.68 | 2019-2025 | |
| Exelixis INC. | $222.02 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $216.65 | 2022-2025 | Brukinsa, Tevimbra |
| Gilead Sciences, INC. | $215.32 | 2019-2025 | Trodelvy |
| Lilly USA, LLC | $198.64 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $194.39 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Stemline Therapeutics INC. | $170.91 | 2023-2025 | Orserdu, Elzonris |
| Karyopharm Therapeutics INC. | $157.20 | 2020-2025 | Xpovio |
| Amgen INC. | $141.91 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Acera Surgical, INC. | $132.36 | 2023 | Restrata Wound Matrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.51 | 2022-2024 | Gilotrif |
| Emd Serono, INC. | $121.71 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $121.35 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Daiichi Sankyo INC. | $116.35 | 2019-2025 | Enhertu |
| Taiho Oncology, INC. | $116.21 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $115.21 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $114.96 | 2022-2025 | |
| Astellas Pharma US INC | $112.55 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Epizyme, INC. | $99.52 | 2021 | |
| Mirati Therapeutics, INC. | $97.20 | 2023-2024 | Krazati |
| Tersera Therapeutics LLC | $88.29 | 2019-2025 | Zoladex |
| Sobi, INC | $86.25 | 2023-2025 | |
| Coherus Oncology, INC. | $82.00 | 2020-2024 | |
| Kite Pharma, INC. | $77.19 | 2019-2023 | |
| Array Biopharma INC | $74.92 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Blueprint Medicines Corporation | $69.48 | 2022-2024 | Ayvakit |
| Ipsen Biopharmaceuticals, INC | $66.12 | 2024-2025 | Onivyde |
| Adc Therapeutics America, INC. | $64.97 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $64.76 | 2022-2025 | Fotivda |
| Springworks Therapeutics, INC. | $46.01 | 2024-2025 | Ogsiveo |
| Pharmaessentia USA Corporation | $41.22 | 2024-2025 | Besremi |
| Morphosys, US INC. | $33.95 | 2023-2024 | Monjuvi |
| Telix Pharmaceuticals | $27.75 | 2024 | Illuccix |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Deciphera Pharmaceuticals INC. | $23.62 | 2025 | Qinlock |
| Alexion Pharmaceuticals, INC. | $21.64 | 2019 | |
| Dendreon Pharmaceuticals LLC | $20.73 | 2025 | Provenge |
| Teva Pharmaceuticals USA, INC. | $16.58 | 2020 | |
| Foundation Medicine, INC. | $16.02 | 2019 | |
| Geron Corporation | $14.98 | 2025 | Rytelo |
| Sirtex Medical INC | $14.89 | 2020 | |
| Adaptive Biotechnologies Corporation | $14.81 | 2023 | Clonoseq |
| Janssen Pharmaceuticals, INC | $14.15 | 2019 | |
| Verastem, INC. | $13.67 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $13.55 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $12.39 | 2019 | |
| Agios Pharmaceuticals, INC. | $10.95 | 2019 | |
| Pharmaand Gmbh | $9.18 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.